We are supporting numerous MPN and MDS trials.
In MPN, we are looking to see if a drug that is already used in breast cancer, will work for people who have MPN who have certain gene changes commonly found in this type of blood cancer. We also want to see if ruxolitinib will work for people with MPN who have relapsed after receiving chemotherapy. Another trial is testing if two drugs that are usually given alone - chemotherapy and ruxolitinib - can be safely given together.
For MDS, we want to improve the way people are treated by fine tuning the drug combinations. We are also supporting trials that want to boost the chances of a successful stem cell transplant, and looking at ways to treat people who have relapsed MDS after a stem cell transplant. And we are finding alternative treatments for older people who have high-risk MDS who are unable to tolerate high intensity chemotherapy.